Replies to post #232864 on NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

For the record Senti, 3 and a half years ago I said here

If I were Dr. Liau or Linda Powers and really believed this stuff might work, I would try to amend the SAP, elevate OS to a co-primary endpoint (or keep as secondary with assigned alpha), and reserve the bulk of the alpha to test OS. (Like the AVAGLio and RTOG0825 trials in nGBM). The FDA would probably kick and scream over that change, especially if an interim occurred.

This was long before they mentioned amending the SAP.